189 related articles for article (PubMed ID: 24749762)
1. White paper on how to go forward with cell-based advanced therapies in Europe.
Erben RG; Silva-Lima B; Reischl I; Steinhoff G; Tiedemann G; Dalemans W; Vos A; Janssen RT; Le Blanc K; van Osch GJ; Luyten FP
Tissue Eng Part A; 2014 Oct; 20(19-20):2549-54. PubMed ID: 24749762
[TBL] [Abstract][Full Text] [Related]
2. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
[TBL] [Abstract][Full Text] [Related]
3. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
5. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
6. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
7. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
8. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT).
Sanchez-Guijo F; Vives J; Ruggeri A; Chabannon C; Corbacioglu S; Dolstra H; Farge D; Gagelmann N; Horgan C; Kuball J; Neven B; Rintala T; Rocha V; Sanchez-Ortega I; Snowden JA; Zwaginga JJ; Gnecchi M; Sureda A
Cytotherapy; 2024 Jul; 26(7):681-685. PubMed ID: 38416085
[TBL] [Abstract][Full Text] [Related]
9. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
[TBL] [Abstract][Full Text] [Related]
10. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
11. The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.
Mahalatchimy A; Rial-Sebbag E; Tournay V; Faulkner A
J Law Soc; 2012; 39(1):131-49. PubMed ID: 22530249
[TBL] [Abstract][Full Text] [Related]
12. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
13. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
14. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
15. Regulation of advanced therapies in Europe: Are we on the right track?
Izeta A; Cuende N
Cell Stem Cell; 2023 Aug; 30(8):1013-1016. PubMed ID: 37541207
[TBL] [Abstract][Full Text] [Related]
16. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
[TBL] [Abstract][Full Text] [Related]
17. European regulatory tools for advanced therapy medicinal products.
Flory E; Reinhardt J
Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
[TBL] [Abstract][Full Text] [Related]
18. Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States.
Ivaskiene T; Mauricas M; Ivaska J
Curr Stem Cell Res Ther; 2017; 12(1):45-51. PubMed ID: 27412678
[TBL] [Abstract][Full Text] [Related]
19. Innovative regenerative medicines in the EU: a better future in evidence?
Corbett MS; Webster A; Hawkins R; Woolacott N
BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
[TBL] [Abstract][Full Text] [Related]
20. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
